img

Global Antibacterial (Drug) Resistance Industry Outlook 2024: Overview, Opportunities, Key Companies and Forecast to 2034


Published on: 2024-01-04 | No of Pages : 320 | Industry : Pharma & Healthcare

Publisher : GRD Survey | Format : PDF

Global Antibacterial (Drug) Resistance Industry Outlook 2024: Overview, Opportunities, Key Companies and Forecast to 2034

Executive Summary

According to GRD Survey data, the global Antibacterial (Drug) Resistance market is estimated at million US$ in 2021 and is expected to reach million US$ by the end of 2028, growing at a CAGR of % in the forecast period between 2022 and 2028.

This report studies the Antibacterial (Drug) Resistance market dynamics from angles such as new entries, mergers and acquisitions, fundings, exit and major technology breakthroughs. Market performance is evaluated through market size (value and volume) by players, regions, product types and end industries. This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis.

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Antibacterial (Drug) Resistance in these regions, from 2016 to 2027, covering
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Italy, Spain and Russia, etc.)
Asia-Pacific (China, Japan, Korea, Southeast Asia, India, Australia)
South America (Brazil, Argentina, Colombia, etc.)
Middle East and Africa (Turkey, Saudi Arabia, South Africa, etc.)

Market Snapshot, By Product Type
Telavancin (Vibativ)
Ceftaroline Fosamil (Teflaro/ Zinforo)
Fidaxomicin (Dificid / Dificlir)
Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio)
Dalbavancin (Dalvance/ Xydalba)
Tedizolid Phosphate (Sivextro)
Oritavancin (Orbactiv/ Nuvocid)
Ceftolozane-Tazobactam (Zerbaxa)
Ceftazidime-Avibactam (Avycaz/ Zavicefta)

Market Snapshot, By Application
Complicated Urinary Tract Infection (CUTI)
Complicated Intra-Abdominal Infections (CIAI)
Blood Stream Infections (BSI)
Clostridium Difficile Infections (CDI)
Acute Bacterial Skin And Skin Structure Infections (ABSSSI)
Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
Community Acquired Bacterial Pneumonia (CABP)

Main Market Players Analyzed in this report, including
VenatoRx Pharmaceuticals
Pfizer
PENDOPHARM
Osel
Novexel
NanoSafe Coatings
Nabriva Therapeutics
Morphochem
Microbecide
Merck
Melinta Therapeutics
Lyndra
Isis Pharmaceuticals
InterMune
GSK
Evolva Holding
Demuris
ContraFect
Cerexa
Aventis Pharma
Austell Laboratories
Assembly Biosciences
Arpida
ANTABIO
Allergan
Acino Holdings
Achaogen
Absynth Biologics
Abbott Laboratories
AAIPharma Services

The study objectives of this report are
To study and analyze the global Antibacterial (Drug) Resistance market size (value & volume) by company, key regions/countries, products and application, history data from 2016 to 2020, and forecast to 2027.
To understand industry structure of Antibacterial (Drug) Resistance market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To identify the key global Antibacterial (Drug) Resistance manufacturers and regional typical players, to define, describe and analyze their sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Antibacterial (Drug) Resistance market with respect to individual growth trends, future prospects, and their contribution to the total market.
To project the value and volume of Antibacterial (Drug) Resistance submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.

In this study, the years considered to estimate the market size of Antibacterial (Drug) Resistance are as follows
History Year2016-2020
Base Year2020
Estimated Year2021
Forecast Year 2021 to 2027

This report includes the estimation of market size in terms of value (million USD) and volume from top-down approach by analyzing major submarkets and their major driving factors, and verified from bottom-up approaches. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified from primary sources.

For the data information by region, company, type and application, 2020 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Key Stakeholders Considered in the study
Raw material vendors
Distributors/traders/wholesalers/suppliers
Regulatory authorities, including government agencies and NGO
Commercial research & development (R&D) institutions
Importers and exporters
Government organizations, research organizations, and consulting firms
Trade/Industrial associations
End-use industries

Table of Content

Table of Contents

1 Market Definition & Scope
1.1 Definition & Scope
1.2 Antibacterial (Drug) Resistance Product Specifications
1.3 Main Events (Entry, M&A, Exit, Technology and Capital Activity)
1.4 Global Antibacterial (Drug) Resistance Market Performance and Outlook

2 Market Development Performance under COVID-19
2.1 Influencing Factors of Industry Development in the Next Five Years
2.1.1 Drivers
2.1.2 Restraints
2.1.3 Opportunities
2.2 Porter’s Five Forces Analysis
2.3 Comparison of Alternatives and Antibacterial (Drug) Resistance

3 Supply Chain and Manufacturing Cost Analysis
3.1 Supply Chain Analysis
3.2 Raw Materials and Key Suppliers Analysis
3.2.1 Raw Materials Introduction
3.2.1 Raw Materials Key Suppliers List
3.3 Antibacterial (Drug) Resistance Sales Channel and Distributors Analysis
3.3.1 Antibacterial (Drug) Resistance Sales Channel
3.3.2 Antibacterial (Drug) Resistance Distributors
3.4 Key Buying Industries/Consumers
3.4.1 Major Buyers in Complicated Urinary Tract Infection (CUTI)
3.4.2 Major Buyers in Complicated Intra-Abdominal Infections (CIAI)
3.5 Antibacterial (Drug) Resistance Manufacturing Cost Structure Analysis

4 Market Segment: by Type
4.1 Antibacterial (Drug) Resistance Type Introduction
4.1.1 Telavancin (Vibativ)
4.1.2 Ceftaroline Fosamil (Teflaro/ Zinforo)
4.1.3 Fidaxomicin (Dificid / Dificlir)
4.1.4 Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio)
4.1.5 Dalbavancin (Dalvance/ Xydalba)
4.1.6 Tedizolid Phosphate (Sivextro)
4.1.7 Oritavancin (Orbactiv/ Nuvocid)
4.1.8 Ceftolozane-Tazobactam (Zerbaxa)
4.1.9 Ceftazidime-Avibactam (Avycaz/ Zavicefta)
4.2 Global Antibacterial (Drug) Resistance Sales by Type 2016-2021
4.3 Global Antibacterial (Drug) Resistance Revenue by Type 2016-2021
4.4 Global Antibacterial (Drug) Resistance Price by Type 2016-2021

5 Market Segment: by Application
5.1 Antibacterial (Drug) Resistance Type Introduction
5.1.1 Complicated Urinary Tract Infection (CUTI)
5.1.2 Complicated Intra-Abdominal Infections (CIAI)
5.1.3 Blood Stream Infections (BSI)
5.1.3 Clostridium Difficile Infections (CDI)
5.1.4 Acute Bacterial Skin And Skin Structure Infections (ABSSSI)
5.1.5 Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
5.1.6 Community Acquired Bacterial Pneumonia (CABP)
5.2 Global Antibacterial (Drug) Resistance Sales by Application 2016-2021
5.3 Global Antibacterial (Drug) Resistance Revenue by Application 2016-2021
5.4 Global Antibacterial (Drug) Resistance Price by Application 2016-2021

6 Marke Segment: by Region
6.1 Global Antibacterial (Drug) Resistance Market by Region
6.1.1 Global Antibacterial (Drug) Resistance Sales by Regions
6.1.2 Global Antibacterial (Drug) Resistance Revenue by Regions
6.2 North America Antibacterial (Drug) Resistance Market 2016-2021
6.3 Europe Antibacterial (Drug) Resistance Market 2016-2021
6.4 Asia Pacific Antibacterial (Drug) Resistance Market 2016-2021
6.5 South America Antibacterial (Drug) Resistance Market 2016-2021
6.6 Middle East and Africa Antibacterial (Drug) Resistance Market 2016-2021

7 North America
7.1 North America Antibacterial (Drug) Resistance Market by Country 2016-2021
7.1.1 North America Antibacterial (Drug) Resistance Sales by Country
7.1.2 North America Antibacterial (Drug) Resistance Revenue by Country
7.2 United States
7.3 Canada
7.4 Mexico

8 Europe
8.1 Europe Antibacterial (Drug) Resistance Market by Country 2016-2021
8.1.1 Europe Antibacterial (Drug) Resistance Sales by Country
8.1.2 Europe Antibacterial (Drug) Resistance Revenue by Country
8.2 Germany
8.3 France
8.4 UK
8.5 Italy
8.6 Russia
8.7 Spain

9 Asia Pacific
9.1 Asia Pacific Antibacterial (Drug) Resistance Market by Country 2016-2021
9.1.1 Asia Pacific Antibacterial (Drug) Resistance Sales by Country
9.1.2 Asia Pacific Antibacterial (Drug) Resistance Revenue by Country
9.2 China
9.3 Japan
9.4 Korea
9.5 Southeast Asia
9.6 India
9.7 Australia

10 South America
10.1 South America Antibacterial (Drug) Resistance Market by Country 2016-2021
10.1.1 South America Antibacterial (Drug) Resistance Sales by Country
10.1.2 South America Antibacterial (Drug) Resistance Revenue by Country
10.2 Brazil
10.3 Argentina
10.4 Colombia

11 Middle East and Africa
11.1 Middle East and Africa Antibacterial (Drug) Resistance Market by Country 2016-2021
11.1.1 Middle East and Africa Antibacterial (Drug) Resistance Sales by Country
11.1.2 Middle East and Africa Antibacterial (Drug) Resistance Revenue by Country
11.2 Turkey
11.3 Saudi Arabia
11.4 South Africa

12 Key Participants Company Information
12.1 VenatoRx Pharmaceuticals
12.1.1 VenatoRx Pharmaceuticals Company Information
12.1.2 VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Product Portfolio, Specification and Application
12.1.3 VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2019-2021)
12.1.4 VenatoRx Pharmaceuticals Key Development
12.2 Pfizer
12.2.1 Pfizer Company Information
12.2.2 Pfizer Antibacterial (Drug) Resistance Product Portfolio, Specification and Application
12.2.3 Pfizer Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2019-2021)
12.2.4 Pfizer Key Development
12.3 PENDOPHARM
12.3.1 PENDOPHARM Company Information
12.3.2 PENDOPHARM Antibacterial (Drug) Resistance Product Portfolio, Specification and Application
12.3.3 PENDOPHARM Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2019-2021)
12.3.4 PENDOPHARM Key Development
12.4 Osel
12.4.1 Osel Company Information
12.4.2 Osel Antibacterial (Drug) Resistance Product Portfolio, Specification and Application
12.4.3 Osel Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2019-2021)
12.4.4 Osel Key Development
12.5 Novexel
12.5.1 Novexel Company Information
12.5.2 Novexel Antibacterial (Drug) Resistance Product Portfolio, Specification and Application
12.5.3 Novexel Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2019-2021)
12.5.4 Novexel Key Development
12.6 NanoSafe Coatings
12.6.1 NanoSafe Coatings Company Information
12.6.2 NanoSafe Coatings Antibacterial (Drug) Resistance Product Portfolio, Specification and Application
12.6.3 NanoSafe Coatings Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2019-2021)
12.6.4 NanoSafe Coatings Key Development
12.7 Nabriva Therapeutics
12.7.1 Nabriva Therapeutics Company Information
12.7.2 Nabriva Therapeutics Antibacterial (Drug) Resistance Product Portfolio, Specification and Application
12.7.3 Nabriva Therapeutics Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2019-2021)
12.7.4 NanoSafe Coatings Key Development
12.9 Microbecide
12.9.1 Microbecide Company Information
12.9.2 Microbecide Antibacterial (Drug) Resistance Product Portfolio, Specification and Application
12.9.3 Microbecide Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2019-2021)
12.9.4 Microbecide Key Development
12.8 Morphochem
12.8.1 Morphochem Company Information
12.8.2 Morphochem Antibacterial (Drug) Resistance Product Portfolio, Specification and Application
12.8.3 Morphochem Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2019-2021)
12.8.4 Morphochem Key Development
12.11 Melinta Therapeutics
12.11.1 Melinta Therapeutics Company Information
12.11.2 Melinta Therapeutics Antibacterial (Drug) Resistance Product Portfolio, Specification and Application
12.11.3 Melinta Therapeutics Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2019-2021)
12.11.4 Melinta Therapeutics Key Development
12.12 Lyndra
12.12.1 Lyndra Company Information
12.12.2 Lyndra Antibacterial (Drug) Resistance Product Portfolio, Specification and Application
12.12.3 Lyndra Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2019-2021)
12.12.4 Lyndra Key Development
12.13 Isis Pharmaceuticals
12.13.1 Isis Pharmaceuticals Company Information
12.13.2 Isis Pharmaceuticals Antibacterial (Drug) Resistance Product Portfolio, Specification and Application
12.13.3 Isis Pharmaceuticals Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2019-2021)
12.13.4 Isis Pharmaceuticals Key Development
12.14 InterMune
12.14.1 InterMune Company Information
12.14.2 InterMune Antibacterial (Drug) Resistance Product Portfolio, Specification and Application
12.14.3 InterMune Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2019-2021)
12.14.4 InterMune Key Development
12.15 GSK
12.15.1 GSK Company Information
12.15.2 GSK Antibacterial (Drug) Resistance Product Portfolio, Specification and Application
12.15.3 GSK Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2019-2021)
12.15.4 GSK Key Development
12.17 Demuris
12.18 ContraFect
12.19 Cerexa
12.20 Aventis Pharma
12.21 Austell Laboratories
12.22 Assembly Biosciences
12.23 Arpida
12.24 ANTABIO
12.25 Allergan
12.26 Acino Holdings
12.27 Achaogen
12.28 Absynth Biologics
12.29 Abbott Laboratories
12.30 AAIPharma Services

13 Global Antibacterial (Drug) Resistance Market Forecast by Region by Type and by Application
13.1 Global Antibacterial (Drug) Resistance Sales, Revenue Forecast 2022-2027
13.2 Global Antibacterial (Drug) Resistance Forecast by Regions
13.2.1 Global Antibacterial (Drug) Resistance Sales Forecast by Region 2022-2027
13.2.2 Global Antibacterial (Drug) Resistance Revenue Forecast by Region 2022-2027
13.3 Global Antibacterial (Drug) Resistance Forecast by Type
13.3.1 Global Antibacterial (Drug) Resistance Sales Forecast by Type 2022-2027
13.3.2 Global Antibacterial (Drug) Resistance Revenue Forecast by Type 2022-2027
13.3.3 Global Antibacterial (Drug) Resistance Price Forecast by Type 2022-2027
13.4 Global Antibacterial (Drug) Resistance Forecast by Application
13.4.1 Global Antibacterial (Drug) Resistance Sales Forecast by Application 2022-2027
13.4.2 Global Antibacterial (Drug) Resistance Revenue Forecast by Application 2022-2027
13.4.3 Global Antibacterial (Drug) Resistance Price Forecast by Application 2022-2027

14 Analyst Views and Conclusions

15 Methodology and Data Source
15.1 Methodology
15.2 Research Data Source
15.2.1 Secondary Data
15.2.2 Primary Data
15.2.3 Market Size Estimation
15.3 Legal Disclaimer

List of Figure

List of Tables

Table 1: Global Antibacterial (Drug) Resistance Production Specifications
Table 2: Drivers in Antibacterial (Drug) Resistance Market
Table 3: Restraints Antibacterial (Drug) Resistance Market
Table 4: Opportunity in Antibacterial (Drug) Resistance Market
Table 5: Comparion of Alternative and Antibacterial (Drug) Resistance
Table 6: Antibacterial (Drug) Resistance Raw Materials Key Suppliers List
Table 7: Antibacterial (Drug) Resistance Distributors List
Table 8: Antibacterial (Drug) Resistance Major Buyers in Complicated Urinary Tract Infection (CUTI)
Table 9: Antibacterial (Drug) Resistance Major Buyers in Complicated Intra-Abdominal Infections (CIAI)
Table 10: Antibacterial (Drug) Resistance Major Buyers in Blood Stream Infections (BSI)
Table 11: Global Antibacterial (Drug) Resistance Sales (K Units) by Type 2016-2021
Table 12: Global Antibacterial (Drug) Resistance Sales Market Share by Type 2016-2021
Table 13: Global Antibacterial (Drug) Resistance Revenue (Million USD) by Type 2016-2021
Table 14: Global Antibacterial (Drug) Resistance Revenue Market Share by Type 2016-2021
Table 15: Global Antibacterial (Drug) Resistance Price by Type 2016-2021
Table 16: Global Antibacterial (Drug) Resistance Sales (K Units) by Application 2016-2021
Table 17: Global Antibacterial (Drug) Resistance Sales Market Share by Application 2016-2021
Table 18: Global Antibacterial (Drug) Resistance Revenue (Million USD) by Application 2016-2021
Table 19: Global Antibacterial (Drug) Resistance Revenue Market Share by Application 2016-2021
Table 20: Global Antibacterial (Drug) Resistance Price by Application 2016-2021
Table 21: Global Antibacterial (Drug) Resistance Sales (K Units) by Region 2016-2021
Table 22: Global Antibacterial (Drug) Resistance Sales Market Share by Region 2016-2021
Table 23: Global Antibacterial (Drug) Resistance Revenue (Million USD) by Region 2016-2021
Table 24: Global Antibacterial (Drug) Resistance Revenue Market Share by Region 2016-2021
Table 25: North America Antibacterial (Drug) Resistance Sales (K Units) by Country 2016-2021
Table 26: North America Antibacterial (Drug) Resistance Sales Market Share by Country 2016-2021
Table 27: North America Antibacterial (Drug) Resistance Revenue (Million USD) by Country 2016-2021
Table 28: North America Antibacterial (Drug) Resistance Revenue Market Share by Country 2016-2021)
Table 29: Europe Antibacterial (Drug) Resistance Sales (K Units) by Country 2016-2021
Table 30: Europe Antibacterial (Drug) Resistance Sales Market Share by Country 2016-2021
Table 31: Europe Antibacterial (Drug) Resistance Revenue (Million USD) by Country 2016-2021
Table 32: Europe Antibacterial (Drug) Resistance Revenue Market Share by Country 2016-2021)
Table 33: Asia Pacific Antibacterial (Drug) Resistance Sales (K Units) by Country 2016-2021
Table 34: Asia Pacific Antibacterial (Drug) Resistance Sales Market Share by Country 2016-2021
Table 35: Asia Pacific Antibacterial (Drug) Resistance Revenue (Million USD) by Country 2016-2021
Table 36: Asia Pacific Antibacterial (Drug) Resistance Revenue Market Share by Country 2016-2021)
Table 37: South America Antibacterial (Drug) Resistance Sales (K Units) by Country 2016-2021
Table 38: South America Antibacterial (Drug) Resistance Sales Market Share by Country 2016-2021
Table 39: South America Antibacterial (Drug) Resistance Revenue (Million USD) by Country 2016-2021
Table 40: South America Antibacterial (Drug) Resistance Revenue Market Share by Country 2016-2021)
Table 41: Middle East and Africa Antibacterial (Drug) Resistance Sales (K Units) by Country 2016-2021
Table 42: Middle East and Africa Antibacterial (Drug) Resistance Sales Market Share by Country 2016-2021
Table 43: Middle East and Africa Antibacterial (Drug) Resistance Revenue (Million USD) by Country 2016-2021
Table 44: Middle East and Africa Antibacterial (Drug) Resistance Revenue Market Share by Country 2016-2021)
Table 45 VenatoRx Pharmaceuticals Company Information
Table 46 VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Product Portfolio, Specification and Application
Table 47 VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2019-2021)
Table 48 Pfizer Company Information
Table 49 Pfizer Antibacterial (Drug) Resistance Product Portfolio, Specification and Application
Table 50 Pfizer Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2019-2021)
Table 51 PENDOPHARM Company Information
Table 52 PENDOPHARM Antibacterial (Drug) Resistance Product Portfolio, Specification and Application
Table 53 PENDOPHARM Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2019-2021)
Table 54 Osel Company Information
Table 55 Osel Antibacterial (Drug) Resistance Product Portfolio, Specification and Application
Table 56 Osel Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2019-2021)
Table 57 Novexel Company Information
Table 58 Novexel Antibacterial (Drug) Resistance Product Portfolio, Specification and Application
Table 59 Novexel Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2019-2021)
Table 60 NanoSafe Coatings Company Information
Table 61 NanoSafe Coatings Antibacterial (Drug) Resistance Product Portfolio, Specification and Application
Table 62 NanoSafe Coatings Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2019-2021)
Table 63 Nabriva Therapeutics Company Information
Table 64 Nabriva Therapeutics Antibacterial (Drug) Resistance Product Portfolio, Specification and Application
Table 65 Nabriva Therapeutics Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2019-2021)
Table 66 Morphochem Company Information
Table 67 Morphochem Antibacterial (Drug) Resistance Product Portfolio, Specification and Application
Table 68 Morphochem Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2019-2021)
Table 69 Microbecide Company Information
Table 70 Microbecide Antibacterial (Drug) Resistance Product Portfolio, Specification and Application
Table 71 Microbecide Antibacterial (Drug) Resistance Sales, Price, Revenue and Gross Margin (2019-2021)
Table 72: Global Antibacterial (Drug) Resistance Sales (K Units) Forecast by Region (2022-2027)
Table 73: Global Antibacterial (Drug) Resistance Sales Market Share Forecast by Region (2012-2027)
Table 74: Global Antibacterial (Drug) Resistance Revenue (Million USD) Forecast by Region (2022-2027)
Table 75: Global Antibacterial (Drug) Resistance Revenue Market Share Forecast by Region (2022-2027)
Table 76: Global Antibacterial (Drug) Resistance Sales (K Units) Forecast by Type (2022-2027)
Table 77: Global Antibacterial (Drug) Resistance Sales Market Share Forecast by Type (2012-2027)
Table 78: Global Antibacterial (Drug) Resistance Revenue (Million USD) Forecast by Type (2022-2027)
Table 79: Global Antibacterial (Drug) Resistance Revenue Market Share Forecast by Type (2022-2027)
Table 80: Global Antibacterial (Drug) Resistance Sales (K Units) Forecast by Applicaion (2022-2027)
Table 81: Global Antibacterial (Drug) Resistance Sales Market Share Forecast by Application (2012-2027)
Table 82: Global Antibacterial (Drug) Resistance Revenue (Million USD) Forecast by Application (2022-2027)
Table 83: Global Antibacterial (Drug) Resistance Revenue Market Share Forecast by Application (2022-2027)


List of Figures

Figure 1: Antibacterial (Drug) Resistance Picture
Figure 2: Global Antibacterial (Drug) Resistance Market Size (Million USD) and Growth Rate (2016-2027)
Figure 3: Porter's Five Forces Analysis
Figure 4: Antibacterial (Drug) Resistance Supply Chain Analysis
Figure 5: Antibacterial (Drug) Resistance Manufacturing Cost Structure Analysis
Figure 6: Product Picture of Telavancin (Vibativ)
Figure 7: Product Picture of Ceftaroline Fosamil (Teflaro/ Zinforo)
Figure 8: Global Antibacterial (Drug) Resistance Sales Market Share by Type, 2020
Figure 9: Global Antibacterial (Drug) Resistance Revenue Market Share by Type, 2020
Figure 10: Antibacterial (Drug) Resistance in Complicated Urinary Tract Infection (CUTI)
Figure 11: Global Antibacterial (Drug) Resistance Market: Complicated Urinary Tract Infection (CUTI) 2016-2021
Figure 12: Antibacterial (Drug) Resistance in Complicated Intra-Abdominal Infections (CIAI)
Figure 13: Global Antibacterial (Drug) Resistance Market: Complicated Intra-Abdominal Infections (CIAI) 2016-2021
Figure 14: Global Antibacterial (Drug) Resistance Sales Market Share by Application, 2020
Figure 15: Global Antibacterial (Drug) Resistance Revenue Market Share by Application, 2020
Figure 16: Global Antibacterial (Drug) Resistance Sales Market Share by Region 2016-2021
Figure 17: Global Antibacterial (Drug) Resistance Revenue Market Share by Region 2016-2021
Figure 18: North America Antibacterial (Drug) Resistance Sales (K Units) Status 2016-2021
Figure 19: North America Antibacterial (Drug) Resistance Revenue (Million USD) Status 2016-2021
Figure 20: Europe Antibacterial (Drug) Resistance Sales (K Units) Status 2016-2021
Figure 21: Europe Antibacterial (Drug) Resistance Revenue (Million USD) Status 2016-2021
Figure 22: Asia Pacific Antibacterial (Drug) Resistance Sales (K Units) Status 2016-2021
Figure 23: Asia Pacific Antibacterial (Drug) Resistance Revenue (Million USD) Status 2016-2021
Figure 24: South America Antibacterial (Drug) Resistance Sales (K Units) Status 2016-2021
Figure 25: South America Antibacterial (Drug) Resistance Revenue (Million USD) Status 2016-2021
Figure 26: Middle East and Africa Antibacterial (Drug) Resistance Sales (K Units) Status 2016-2021
Figure 27: Middle East and Africa Antibacterial (Drug) Resistance Revenue (Million USD) Status 2016-2021
Figure 28: North America Antibacterial (Drug) Resistance Sales Market Share by Country, 2020
Figure 29: North America Antibacterial (Drug) Resistance Revenue Market Share by Country, 2020
Figure 30: United States Antibacterial (Drug) Resistance Sales (K Units) Status 2016-2021
Figure 31: United States Antibacterial (Drug) Resistance Revenue (Million USD) Status 2016-2021
Figure 32: Canada Antibacterial (Drug) Resistance Sales (K Units) Status 2016-2021
Figure 33: Canada Antibacterial (Drug) Resistance Revenue (Million USD) Status 2016-2021
Figure 34: Mexico Antibacterial (Drug) Resistance Sales (K Units) Status 2016-2021
Figure 35: Mexico Antibacterial (Drug) Resistance Revenue (Million USD) Status 2016-2021
Figure 36: Europe Antibacterial (Drug) Resistance Sales Market Share by Country, 2020
Figure 37: Europe Antibacterial (Drug) Resistance Revenue Market Share by Country, 2020
Figure 38: Germany Antibacterial (Drug) Resistance Sales (K Units) Status 2016-2021
Figure 39: Germany Antibacterial (Drug) Resistance Revenue (Million USD) Status 2016-2021
Figure 40: France Antibacterial (Drug) Resistance Sales (K Units) Status 2016-2021
Figure 41: France Antibacterial (Drug) Resistance Revenue (Million USD) Status 2016-2021
Figure 42: UK Antibacterial (Drug) Resistance Sales (K Units) Status 2016-2021
Figure 43: UK Antibacterial (Drug) Resistance Revenue (Million USD) Status 2016-2021
Figure 44: Italy Antibacterial (Drug) Resistance Sales (K Units) Status 2016-2021
Figure 45: Italy Antibacterial (Drug) Resistance Revenue (Million USD) Status 2016-2021
Figure 46: Russia Antibacterial (Drug) Resistance Sales (K Units) Status 2016-2021
Figure 46: Russia Antibacterial (Drug) Resistance Revenue (Million USD) Status 2016-2021
Figure 47: Spain Antibacterial (Drug) Resistance Sales (K Units) Status 2016-2021
Figure 48: Spain Antibacterial (Drug) Resistance Revenue (Million USD) Status 2016-2021
Figure 49: Asia Pacific Antibacterial (Drug) Resistance Sales Market Share by Country, 2020
Figure 50: Asia Pacific Antibacterial (Drug) Resistance Revenue Market Share by Country, 2020
Figure 51: China Antibacterial (Drug) Resistance Sales (K Units) Status 2016-2021
Figure 52: China Antibacterial (Drug) Resistance Revenue (Million USD) Status 2016-2021
Figure 53: Japan Antibacterial (Drug) Resistance Sales (K Units) Status 2016-2021
Figure 54: Japan Antibacterial (Drug) Resistance Revenue (Million USD) Status 2016-2021
Figure 55: Korea Antibacterial (Drug) Resistance Sales (K Units) Status 2016-2021
Figure 56: Korea Antibacterial (Drug) Resistance Revenue (Million USD) Status 2016-2021
Figure 57: Southeast Asia Antibacterial (Drug) Resistance Sales (K Units) Status 2016-2021
Figure 58: Southeast Asia Antibacterial (Drug) Resistance Revenue (Million USD) Status 2016-2021
Figure 59: India Antibacterial (Drug) Resistance Sales (K Units) Status 2016-2021
Figure 60: India Antibacterial (Drug) Resistance Revenue (Million USD) Status 2016-2021
Figure 61: Australia Antibacterial (Drug) Resistance Sales (K Units) Status 2016-2021
Figure 62: Australia Antibacterial (Drug) Resistance Revenue (Million USD) Status 2016-2021
Figure 63: South America Antibacterial (Drug) Resistance Sales Market Share by Country, 2020
Figure 64: South America Antibacterial (Drug) Resistance Revenue Market Share by Country, 2020
Figure 65: Brazil Antibacterial (Drug) Resistance Sales (K Units) Status 2016-2021
Figure 66: Brazil Antibacterial (Drug) Resistance Revenue (Million USD) Status 2016-2021
Figure 67: Argentina Antibacterial (Drug) Resistance Sales (K Units) Status 2016-2021
Figure 68: Argentina Antibacterial (Drug) Resistance Revenue (Million USD) Status 2016-2021
Figure 69: Colombia Antibacterial (Drug) Resistance Sales (K Units) Status 2016-2021
Figure 70: Colombia Antibacterial (Drug) Resistance Revenue (Million USD) Status 2016-2021
Figure 71: Middle East and Africa Antibacterial (Drug) Resistance Sales Market Share by Country, 2020
Figure 72: Middle East and Africa Antibacterial (Drug) Resistance Revenue Market Share by Country, 2020
Figure 73: Turkey Antibacterial (Drug) Resistance Sales (K Units) Status 2016-2021
Figure 74: Turkey Antibacterial (Drug) Resistance Revenue (Million USD) Status 2016-2021
Figure 75: Saudi Arabia Antibacterial (Drug) Resistance Sales (K Units) Status 2016-2021
Figure 76: Saudi Arabia Antibacterial (Drug) Resistance Revenue (Million USD) Status 2016-2021
Figure 77: South Africa Antibacterial (Drug) Resistance Sales (K Units) Status 2016-2021
Figure 78: South Africa Antibacterial (Drug) Resistance Revenue (Million USD) Status 2016-2021
Figure 79: VenatoRx Pharmaceuticals Antibacterial (Drug) Resistance Revenue Market Share Globally (2019-2021)
Figure 80: Pfizer Antibacterial (Drug) Resistance Revenue Market Share Globally (2019-2021)
Figure 81: PENDOPHARM Antibacterial (Drug) Resistance Revenue Market Share Globally (2019-2021)
Figure 82: Osel Antibacterial (Drug) Resistance Revenue Market Share Globally (2019-2021)
Figure 83: Novexel Antibacterial (Drug) Resistance Revenue Market Share Globally (2019-2021)
Figure 84: NanoSafe Coatings Antibacterial (Drug) Resistance Revenue Market Share Globally (2019-2021)
Figure 85: Nabriva Therapeutics Antibacterial (Drug) Resistance Revenue Market Share Globally (2019-2021)
Figure 86: Morphochem Antibacterial (Drug) Resistance Revenue Market Share Globally (2019-2021)
Figure 87: Microbecide Antibacterial (Drug) Resistance Revenue Market Share Globally (2019-2021)
Figure 88: Merck Antibacterial (Drug) Resistance Revenue Market Share Globally (2019-2021)
Figure 89: Global Antibacterial (Drug) Resistance Sales (K Units) Forecast (2022-2027)
Figure 90: Global Antibacterial (Drug) Resistance Sales (K Units) Forecast (2022-2027)